Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly vs Standard Eribulin in HER2-negative Breast Cancer
NCT06857305Phase 3Enrolling by invitation
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eribulin in breast cancer (2 arms). Primary endpoint: Clinical Benefit Rate at 8 weeks. Started Jul 2023; status: enrolling by invitation.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06857305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857305.